Eagle's Eye View: Your Weekly CV Update From ACC.org

By: American College of Cardiology
Listen for free

  • Summary

  • The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
    American College of Cardiology Foundation. All rights reserved.
    Show more Show less
activate_WEBCRO358_DT_T2
Episodes
  • Eight Practice-Changing Trials Featured at ESC Congress 2024

    Eight Practice-Changing Trials Featured at ESC Congress 2024
    Sep 12 2024
    In this special edition of Eagle’s Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF. Subscribe to Eagle’s Eye View
    Show more Show less
    11 mins
  • Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients

    Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients
    Sep 11 2024

    In this week’s View, Dr. Eagle looks at temporary mechanical circulatory support in infarct-related cardiogenic shock. He then explores the anticoagulation benefit in device-detected atrial fibrillation with or without vascular disease as reported in a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Finally, Dr. Eagle discusses a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials that documented the effectiveness of semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction.

    Subscribe to Eagle’s Eye View

    Show more Show less
    8 mins
  • SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants

    SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants
    Sep 4 2024

    In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery.

    Subscribe to Eagle’s Eye View

    Show more Show less
    10 mins
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about Eagle's Eye View: Your Weekly CV Update From ACC.org

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available